



#151F
CJH
Patent
Attorney's Docket No. 012712-155
2/18/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Darrell R. ANDERSON et al., ROON,) Group Art Unit: 1816
Application No.: 08/476,275) Examiner: R. Schwadron
Filed: June 7, 1995)
For: THERAPEUTIC APPLICATION OF)
CHIMERIC AND RADIOLABELED)
ANTIBODIES TO HUMAN B)
LYMPHOCYTE RESTRICTED)
DIFFERENTIATION ANTIGEN FOR)
TREATMENT OF B CELL LYMPHOMA)

REPLY AND AMENDMENT PURSUANT TO 37 C.F.R. §§ 1.111, 1.115 AND
1.119 AND SUBMISSION OF DECLARATIONS BY DARRELL R. ANDERSON
PURSUANT TO 37 C.F.R. § 1.132

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Office Action dated June 24, 1996, kindly amend the above-identified application as follows:

IN THE CLAIMS

Please amend the claims as follows:

5
19. (Amended) A (The) method (of claim 18 when) for the treatment of B cell lymphoma comprising the steps of:

F1
1) administering, at a first administration period, an immunologically active chimeric anti-CD20 antibody to a human, wherein said chimeric anti-CD20 antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the